<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-5173-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOXEROL 40MG POWDER FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gensenta &#x130;la&#xE7; Sanayi ve Ticaret A.&#x15E;" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gensenta İlaç Sanayi ve Ticaret A.Ş
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GENSENTA İLAÇ SANAYI VE TICARET A.Ş
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>PANTOXEROL is white powder for injection. It is presented in colorless glass vial containing 40 mg powder with rubber closure and sealed aluminum flip-off cap.</p><p>PANTOXEROL contains the active substance pantoprazole. PANTOXEROL is a medicine called &ldquo;proton pump inhibitor&rdquo;. It reduces the amount of acid produced in your stomach. It is used for treating acid-related diseases of the stomach and intestine.</p><p>This preparation is injected into a vein and will only be given to you if your doctor thinks pantoprazole injections are more suitable for you at the moment than pantoprazole tablets. Tablets will replace your injections as soon as your doctor sees fit.</p><p>&nbsp;</p><p>PANTOXEROL is used in:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of inflammation of the esophagus accompanied by the regurgitation of stomach acid (esophageal reflux disease) and pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Ulcers in the upper part of the intestines (duodenal ulcer) or ulcers in the stomach (gastric ulcers).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of conditions, producing too much acid in the stomach such as Zollinger-Ellison-Syndrome.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all instructions given to you by your doctor. These instructions may be different than the information given in this leaflet.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp; </strong><strong>Do not use </strong><strong>PANTOXEROL</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to the active substance pantoprazole, or to any of the excipients of PANTOXEROL, benzimidazoles (medicine used for fungal diseases).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to other medicines containing other proton pump inhibitors.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp; </strong><strong>Take special care with </strong><strong>PANTOXEROL</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems; please tell your doctor if you ever had problems with your liver. During the PANTOXEROL treatment, especially in long-term use, your doctor will control your liver enzymes regularly. In the case of a rise of liver enzymes PANTOXEROL treatment should be stopped.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with PANTOXEROL may suppress cancer associated symptoms and ultimately could cause delay in the diagnosis. Therefore your doctor may perform some tests to you in order to be sure that you are not a cancer patient. If your symptoms continue during the treatment further investigations may be required.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking a medicine containing atazanavir for the treatment of HIV-infection at the same time as PANTOXEROL, inform your doctor about this situation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you have osteoporosis (bone loss) disease, tell your doctor. Because PANTOXEROL like all proton pump inhibitors, if used in high doses and over long durations (a year or longer), modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognized risk factors. In these circumstances your doctor may recommend to use PANTOXEROL in lower doses or shorter period.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are previously diagnosed with hypomagnesemia (low magnesium mineral level in your blood) tell your doctor. Because PANTOXEROL, like all other proton pump inhibitors, may cause hypomagnesemia after at least 3 months (generally more than 1 year) treatment. In this case, your doctor may decide for you to take magnesium supplements or to keep PANTOXEROL treatment shorter. During PANTOXEROL treatment if you feel your heart beats abnormally fast, slow or irregular, if you have fatigue or dizziness, muscle spasms or seizure tell your doctor. Because these symptoms may be associated with hypomagnesemia. Also tell your doctor if you are using other drugs. Hypomagnesemia may cause decrease in potassium and calcium levels in the blood. Your doctor may want to follow the magnesium levels in your blood regularly, if it is considered necessary.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you have neuroendocrine tumor diagnostic tests, because PANTOXEROL like all proton pump inhibitors may affect these tests results.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; PANTOXEROL like all proton pump inhibitors may slightly increase the number of certain bacteria normally existing in the upper gastrointestinal tract and accordingly infection risk (<em>Salmonella </em>and <em>Campylobacter</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are using drugs which affect the thickening, or thinning of the blood such as warfarin and phenprocoumon, you may need further checks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had a skin reaction after treatment with a medicine similar to PANTOXEROL that reduces stomach acid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with PANTOXEROL. Remember to also mention any other ill-effects like pain in your joints.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>IMMEDIATELY</strong> consult your doctor if you notice any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An unintentional loss of weight,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, particularly if repeated,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in swallowing,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting blood; this may appear as dark coffee grounds in your vomit,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Looking pale and feeling weak (anemia),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in the stool; which may be black or tarry in appearance,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe and/or persistent diarrhea, this medicine has been associated with a small increase in infectious diarrhea.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>PANTOXEROL is not recommended for use in children as it has not been proven to work in children below 18 years of age.</p><p>&nbsp;</p><p>If these warnings are valid for you, even for a period of time in the past, please consult your doctor.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp; </strong><strong>Taking/using other medicines</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Pantoprazole may diminish the effects of medicines whose absorption related to the acid level (pH) in stomach, such as ketoconazole, itraconazole and posaconazole used to treat fungal infections or erlotinib used for certain types of cancer, by reducing the absorption.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Proton pump inhibitors reduce absorption of medicines for the treatment of HIV (AIDS), such as atazanavir. Co-administration of proton pump inhibitors, including pantoprazole, with atazanavir is not recommended.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Pantoprazole is metabolized in the liver. Also there can be an interaction between pantoprazole with other drugs that are metabolized in the liver. However, special tests were made with the following drugs and no clinical significant interactions were observed:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine (used for epilepsy and mood changes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diazepam (used in removing anxiety disorder)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nifedipine (used for treating elevated blood pressure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glibenclamide (blood sugar lowering)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Birth control pills (containing levonorgestrel and ethinyl estradiol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are using medicine (such as phenprocoumon / warfarin) which effects blood clotting, after initiation of pantoprazole treatment and termination and during irregular use it is recommended to monitor your blood clotting values.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; No interaction has been observed when used with antacids. Antacids are drugs, usually in the form of chewable tablets or syrup, used to reduce gastric acid instantly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate (used to treat rheumatoid arthritis, psoriasis, and cancer) &ndash; if you are taking methotrexate your doctor may temporarily stop your PANTOXEROL treatment because pantoprazole can increase levels of methotrexate in the blood.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fluvoxamine (used to treat depression and other psychiatric diseases) &ndash; if you are taking fluvoxamine your doctor may reduce the dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (used to treat infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s wort (Hypericum perforatum) (used to treat mild depression)</p><p>&nbsp;</p><p><em>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription.</em></p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp; </strong><strong>Using </strong><strong>PANTOXEROL</strong><strong> with food and drink</strong></p><p>There is no interaction with food or drink because of its administration method.</p><p>&nbsp;</p><p><strong>e.&nbsp;&nbsp;&nbsp; </strong><strong>&nbsp;Pregnancy and breast-feeding</strong></p><p>Consult your doctor or pharmacist before administration of this drug.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p><em>Consult your doctor or pharmacist before using this drug.</em></p><p><em>&nbsp;</em></p><p>This medicine should be used in pregnancy, only if the benefit of the drug for the mother greater than the potential risk for the baby.</p><p>&nbsp;</p><p><em>During your treatment, if you realize that you&rsquo;re pregnant, consult your doctor or pharmacist immediately.</em></p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><em>Consult your doctor or pharmacist before using this drug.</em></p><p><em>&nbsp;</em></p><p>This medicine should be used in breast-feeding mothers, only if the benefit of the drug for the mother greater than the potential risk for the unborn child.</p><p>&nbsp;</p><p><strong>f.&nbsp;&nbsp;&nbsp; </strong><strong>Driving and using machines</strong></p><p>If you experience side effects like dizziness or disturbed vision do not drive or operate machines.</p><p>&nbsp;</p><p><strong>g.&nbsp;&nbsp; </strong><strong>Important information about some of the ingredients in </strong><strong>PANTOXEROL</strong></p><p>This medicinal product contains less than 1 mmol of sodium (23 mg) in each vial. No side effects are expected due to this dose of sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Always use </em><em>PANTOXEROL</em><em> exactly as your doctor or pharmacist has told you. You should check with your doctor pharmacist if you are not sure.</em></p><p>&nbsp;</p><p><strong>Instructions for proper use and dose/frequency of administration</strong></p><p>&nbsp;</p><p><u>In treatment of ulcer in upper parts of intestines (duodenal ulcer), stomach ulcer (gastric ulcer) and inflammation of the esophagus accompanied by the regurgitation of stomach acid and pain (reflux esophagitis and gastroesophageal reflux disease):</u></p><p>Daily 1 vial (40 mg pantoprazole).</p><p>&nbsp;</p><p><u>In treatment of Zollinger-Ellison Syndrome and conditions in which too much stomach acid is produced:</u></p><p>Daily 2 vial (80 mg pantoprazole).</p><p>&nbsp;</p><p>Your doctor will determine the dose, depending on the amount of stomach acid you produce.</p><p>&nbsp;</p><p>If you are prescribed more than two vials (80 mg) daily by your doctor, the injections should be given in two equal doses.</p><p>&nbsp;</p><p>Your doctor may initiate treatment with a temporary dose of more than four vials (160 mg) a day. If your stomach acid level needs to be controlled rapidly, a starting dose of 160 mg (four vials) should be enough to lower the amount of stomach acid sufficiently.</p><p>&nbsp;</p><p><strong>Method and route of administration</strong></p><p>Intravenous administration is recommended in case of oral administration is not possible.</p><p>&nbsp;</p><p>A doctor or nurse will administer PANTOXEROL slowly into a vein.</p><p>&nbsp;</p><p><strong>Different age groups</strong></p><p><strong>&nbsp;</strong></p><p><strong>Use in children</strong></p><p>This injection is not recommended for use in patients under 18 years.</p><p>&nbsp;</p><p><strong>Use in elderly</strong></p><p>PANTOXEROL can be used in elderly patients without dose adjustment.</p><p>&nbsp;</p><p><strong>Liver/kidney insufficiency</strong></p><p>No dose adjustment is needed in patients with impaired kidney functions.</p><p>In patients with severe liver problems, the daily dose of 20 mg (half a vial) should not be exceeded.</p><p>&nbsp;</p><p><em>If you have the impression that the effect of </em><em>PANTOXEROL</em><em> is too strong or too weak, please contact your doctor or pharmacist.</em></p><p><em>&nbsp;</em></p><p><strong>a.&nbsp;&nbsp; </strong><strong>If you are given more PANTOXEROL than you should</strong></p><p>There are no known symptoms of overdose. If you have received more PANTOXEROL than you should, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp; </strong><strong>If you forget to use PANTOXEROL</strong></p><p>If you forget to use your medicine, do not take a double dose to make up for the forgotten dose. Continue your treatment, according to the dosing schedule given by your doctor, from the next dose.</p><p>&nbsp;</p><p><em>Do not take a double dose to make-up for a forgotten dose.</em></p><p><em>&nbsp;</em></p><p><strong>c.&nbsp;&nbsp;&nbsp; </strong><strong>If you stop using PANTOXEROL</strong></p><p>Your doctor will tell you how long your treatment with PANTOXEROL will take. Do not stop your treatment early, because the symptoms of your illness may return, or may exacerbate.</p><p>&nbsp;</p><p><em>If you have any further questions on the use of this product, ask your doctor or pharmacist.</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong><strong>SERIOUS SIDE EFFECTS:</strong></p><p><strong>If you experience any of the following, stop using PANTOXEROL</strong><strong> and tell your doctor IMMEDIATELY or contact the emergency department at the nearest hospital to you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious allergic reactions (frequency rare: </strong>may affect up to 1 in 1,000 people<strong>):</strong> Swelling of the tongue and/or throat, difficulty in swallowing, hives (nettle rash), difficulties in breathing, allergic facial swelling (Quincke&rsquo;s edema/angioedema), severe dizziness with very fast heartbeat and heavy sweating.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious skin conditions (frequency not known:</strong> frequency cannot be estimated from the available data<strong>)</strong><strong>:</strong> Painful rash with rapid widespread blistering of the skin and rapid deterioration of your general condition, erosion (including slight bleeding) of eyes, nose, mouth/lips or genitals (These may be signs of severe skin reactions like Stevens-Johnson-Syndrome, Lyell-Syndrome, Erythema multiforme), and sensitivity to light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other serious conditions (frequency not known:</strong> frequency cannot be estimated from the available data<strong>):</strong> Yellowing of the skin or whites of the eyes (severe damage to liver cells, jaundice) or fever, rash, and enlarged kidneys sometimes with painful urination, and lower back pain (serious inflammation of the kidneys) possibly leading to kidney failure.</p><p>&nbsp;</p><p>These are very serious side effects.</p><p>&nbsp;</p><p>If you have any of these, it means you have a serious allergy to PANTOXEROL. You may need emergency medical attention or to be hospitalized.</p><p>&nbsp;</p><p><strong>Possible side effects:</strong></p><p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>If you experience any of the following below, inform your doctor.</strong></p><p>&nbsp;</p><p><strong>&bull; Common (may affect up to 1 to 10 in 100 patients)</strong></p><p>Inflammation of the wall of the vein and blood clotting (thrombophlebitis) where the medicine is injected; benign polyps in the stomach.</p><p>&nbsp;</p><p><strong>&bull; Uncommon (may affect up to 1 to 10 in 1000 patients)</strong></p><p>Headache; dizziness; diarrhea; feeling sick, vomiting; bloating and flatulence (wind); constipation; dry mouth; abdominal pain and discomfort; allergic reactions like rash, itching, skin rash; feeling weak, sleep disorders.</p><p>&nbsp;</p><p>Taking a proton pump inhibitor like pantoprazole, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids which can increase the risk of osteoporosis.</p><p>&nbsp;</p><p><strong>&bull; Rare (may affect up to 1 to 10 in 10.000 patients)</strong></p><p>Distortion or complete lack of the sense of taste; disturbances in vision such as blurred vision; hives; pain in the joints; muscle pains; weight changes; raised body temperature; high fever; swelling of the extremities (peripheral edema); allergic reactions; depression; breast enlargement in males (gynecomasty).</p><p>&nbsp;</p><p><strong>&bull; Very Rare (may affect less than 1 in 10.000 patients)</strong></p><p>Disorientation.</p><p>&nbsp;</p><p><strong>&bull; Not known (frequency cannot be estimated from the available data)</strong></p><p>Seeing or hearing things that aren&#39;t really there (hallucination) especially in susceptible patients, loss of harmony of space and time, a state of mental confusion; decreased sodium level in blood (hyponatremia). If you are using PANTOXEROL for more than three months, it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium (hypomagnesemia) can be seen as fatigue, involuntary muscle contractions, convulsions, increased heart rate. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in your blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</p><p>&nbsp;</p><p><strong>Side effects identified through blood tests</strong></p><p><strong>&nbsp;</strong></p><p><strong>&bull; Uncommon (may affect up to 1 to 10 in 1000 patients)</strong></p><p>An increase in liver enzymes.</p><p>&nbsp;</p><p><strong>&bull; Rare (may affect up to 1 to 10 in 10.000 patients)</strong></p><p>An increase in bilirubin level in blood; increased (triglyceride) fat levels in blood; sharp drop in circulating granular white blood cells (leucocyte), (associated with high fever).</p><p>&nbsp;</p><p><strong>&bull; Very Rare (may affect less than 1 in 10.000 people)</strong></p><p>A reduction in the number of blood cells responsible for blood clotting (platelets), (this condition may cause you to bleed more than normal); a reduction in the number of white blood cells (leucocyte), (this condition may lead to more frequent infections); coexisting abnormal reduction in the number of red blood cells (erythrocyte) and white blood cells as well as platelets that are responsible for blood clotting.</p><p>&nbsp;</p><p><em>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton or vial. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store at room temperature below 30&deg;C. &nbsp;Store in the original package.</p><p>&nbsp;</p><p>After the reconstitution, or reconstitution and dilution, chemical and physical in-use stability has been demonstrated for 12 hours at 30&deg;C. From a microbiological point of view, the product should be used immediately.</p><p>&nbsp;</p><p>Do not use PANTOXEROL if you notice any defect in the product and/or on the packaging.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong><em>Active Substance: </em></strong>Each vial contains 42.3 mg pantoprazole sodium equivalent to 40 mg pantoprazole.</p><p><strong><em>Excipient(s): </em></strong>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                PANTOXEROL is white powder for injection. It is presented in colorless glass vial containing 40 mg powder closed with rubber closure and sealed with an aluminum flip-off cap. One vial is inserted into printed carton, together with its leaflet.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>MN Pharmaceuticals</p><p>Prof. Dr. B&uuml;lent Tarcan Sok., Pak İş Merkezi No: 5/1</p><p>34349 Gayrettepe &ndash; Istanbul/TURKEY</p><p>Tel: +90 212 337 38 00</p><p>Fax: +90 212 337 38 01</p><p>e-mail : info@mn.com.tr</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>MN Pharmaceuticals</p><p>Sanayi Cad. No: 13</p><p>Yenibosna, Bah&ccedil;elievler &ndash; Istanbul/TURKEY</p><p>Tel:&nbsp;+90 212 454 76 00</p><p>Fax:&nbsp;+90 212 454 76 96</p><p>e-mail: info@mn.com.tr</p><p>&nbsp;</p><p><em>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</em></p><p>Kingdom of Saudi Arabia</p><p>Salehiya Trading Est.</p><p>P.O. Box: 991 Riyadh: 11421</p><p>Tel. No.: +966 11 464 6955</p><p>Fax No.: +966 11 463 4362</p><p>Website: www.salehiya.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 06/2018; version number 03
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">بانتوكسيرول هو مسحوق للحقن أبيض. يقدم في قارورة زجاجية غير ملونة تحتوي على 40 ملغم مسحوق بسدادة مطاطية و غطاء ألمنيوم مغلق بفتح علوي.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يحتوي بانتوكسيرول على المادة الفعالة بانتوبرازول. بانتوكسيرول عبارة عن دواء يدعى &quot;مثبط مضخة بروتون&quot;. يقوم بتقليل الحمض الناتج في معدتك. يستخدم في علاج الأمراض المتعلقة بالحموضة في المعدة و الأمعاء.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يتم حقن المستحضر في الوريد و يعطى فقط إذا اعتقد الطبيب أن حقن بانتوبرازول أنسب لك من أقراص بانتوبرازول في تلك اللحظة. سوف يتم استبدال الحقن بالأقراص في اقرب وقت يرى طبيبك ذلك مناسبا.ً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يستخدم بانتوكسيرول في:</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج التهاب المريء مصحوباً بارتداد حمض المعدة (مرض جريان رجوعي مريئي) و الألم.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات في الجزء العلوي من الأمعاء (قرحة اثنا عشرية) أو تقرحات في المعدة (تقرحات معدية).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج الحالات، انتاج الحمض الزائد في المعدة مثل متلازمة زولنغر-إليسون.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">اتبع جميع تعليمات الطبيب. هذه التعليمات قد تختلف عن المعلومات المذكورة في هذه النشرة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>أ. لا تستخدم </strong><strong>بانتوكسيرول</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية (فرط حساسية) تجاه المادة الفعالة بانتوبرازول أو لأي مسوغات بانتوكسيرول، بنزإيميدازولات (دواء يستخدم في الأمراض الفطرية).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه الأدوية التي تحتوي على مثبطات مضخة البروتون الأخرى.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>ب. تعامل مع </strong><strong>بانتوكسيرول</strong><strong> بعناية خاصة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل كبدية شديدة؛ الرجاء اعلام طبيبك إذا كان لديك في أي وقت مضى أي مشاكل في الكبد. خلال العلاج باستخدام بانتوكسيرول خاصة الاستخدام طويل المدى، سيراقب طبيبك إنزيمات الكبد بشكل منتظم. يجب إيقاف العلاج باستخدام بانتوكسيرول في حال ارتفاع إنزيمات الكبد.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يخفي العلاج باستخدام بانتوكسيرول الأعراض المصاحبة للسرطان مما قد يؤدي في الأساس إلى تأخير التشخيص. لذا قد يقوم طبيبك بإجراء اختبارات لك ليتأكد من أنك لست مريضا بالسرطان. إذا استمرت أعراضك خلال العلاج فقد تكون هناك حاجة لفحوصات إضافية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ دواء يحتوي على أتازانافير لعلاج عدوى نقص المناعة المكتسبة HIV في الوقت نفسه مع بانتوكسيرول، فقم باعلام طبيبك عن الوضع.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض هشاشة العظام (فقدان عظم)، أخبر طبيبك. لأن بانتوكسيرول كسائر مثبطات مضخة البروتون إذا تم استخدامه بجرعات عالية و على فترات طويلة (لسنة أو أكثر)، فإنه يزيد بشكل بسيط احتمال العرضة لكسر في الورك، الرسغ و العمود الفقري غالبا لدى المسنين أو في حال وجود عوامل اختطار معروفة أخرى. في هذه الحالات، قد ينصح طبيبك باستخدام بانتوكسيرول بجرعات أقل أو لفترة أقصر.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم تشخيصك بنقص المغنيسيوم الدم (مستوى منخفض لمعدن المغنيسيوم في دمك) من قبل فقم باعلام طبيبك. لأن بانتوكسيرول كسائر مثبطات مضخة البروتون قد يسبب نقص مغنيسيوم الدم بعد 3 أشهر على الأقل من العلاج (بشكل عام أكثر من سنة). في هذه الحالة قد يقرر طبيبك أن تأخذ مكملات المغنيسوم أو إبقاء فترة العلاج باستخدام بانتوكسيرول أقصر. إذا أحسست خلال فترة العلاج باستخدام بانتوكسيرول بأن دقات قلبك سريعة، بطيئة أو غير منتظمة بشكل غير طبيعي، أو أحسست بالتعب أو الدوار، تقلصات عضلية أو النوبة فقم باعلام طبيبك. لأن هذه الأعراض قد تكون مرتبطة بنقص مغنيسيوم الدم. قم أيضا باعلام طبيبك إذا كنت تستخدم أدوية أخرى. قد يسبب نقص مغنيسيوم الدم بانخفاض مستويات البوتاسيوم و الكالسيوم في الدم. قد يرغب طبيبك بمراقبة مستويات المغنيسيوم في دمك بشكل منتظم إذا كان ذلك ضروريا.ً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم باعلام طبيبك إذا كان لديك فحوصات تشخيصية لورم عصبي صماوي لأن بانتوكسيرول كسائر مثبطات مضخة البروتون قد يؤثر على نتيجة هذه الفحوصات.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يزيد بانتوكسيرول كسائر مثبطات مضخة البروتون عدد بكتيريا معينة والموجودة طبيعيا في الجزء العلوي من الجهاز الهضمي بشكل طفيف و بذلك يزيد خطر العرضة للالتهاب (<em>سالمونيلا</em> و <em>كامبيلوباكتر</em>).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم أدوية تؤثر على ثخونة أو رقة الدم مثل وارفارين و فينبروكومون فقد تحتاج للمزيد من الفحوصات.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حصل لديك في اي وقت مضى ردة فعل جلدية بعد العلاج بدواء مشابه ل بانتوكسيرول و الذي يعمل على خفض حموضة المعدة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظهر طفح جلدي على بشرتك، خاصة في المناطق المعرضة للشمس أخبر طبيبك بأسرع ما يمكن، فقد تحتاج لوقف العلاج ب بانتوكسيرول. لا تنسى ايضا أن تذكر أي آثار مرضية أخرى مثل ألم المفاصل.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استشر طبيبك <strong>فورا</strong> إذا لاحظت أي من التالي:</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان وزن غير مقصود،</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ، خاصة إن كان متكررا،ً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع،</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقيؤ الدم؛ قد يظهر هذا كالقهوة الداكنة المطحونة في القيء.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشحوب و الشعور بالضعف (فقر الدم)،</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البراز؛ والذي قد يكون ذا مظهر اسود او قطراني،</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الشديد و/أو المستمر، ارتبط هذا الدواء مع زيادة بسيطة في التهاب معدي معوي.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الاطفال و المراهقين</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا يوصى باستخدام بانتوكسيرول في الاطفال حيث لم تثبت فعاليته عند الأطفال دون سن 18 عاما.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كانت هذه المحاذير تنطبق عليك حتى ولو في فترة من الماضي، يرجى استشارة طبيبك.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>ج. أخذ/استخدام أدوية أخرى</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقلص بانتوبرازول تأثير الأدوية التي يرتبط امتصاصها بدرجة الحموضة (pH) في المعدة عبر تقليل الامتصاص مثل كيتوكونازول، إيتراكونازول و بوزاكونازول الذين يستخدمون في علاج الالتهابات الفطرية أو إيرلوتينيب الذي يستخدم لأنواع معينة من السرطان.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلل مثبطات مضخة البروتون امتصاص الأدوية التي تستخدم في علاج نقص المناعة المكتسبة HIV (AIDS) مثل أتازانافير. لا ينصح بالاستخدام المتزامن لمثبطات مضخة البروتون كبانتوبرازول مع أتازانافير.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بانتوبرازول يستقلب في الكبد. قد يحصل أيضا تفاعل بين بانتوبرازول و الأدوية الأخرى التي يتم استقلابها في الكبد. لكن تم إجراء اختبارات معينة مع الأدوية التالية و لم تتم ملاحظة تفاعلات ذات أهمية سريرية:</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين (يستخدم للصرع و تقلبات المزاج)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديازيبام (يستخدم في إزالة اضطرابات القلق)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفيديبين (يستخدم في علاج ارتفاع ضغط الدم)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلايبينكلامايد (يخفض سكر الدم)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حبوب منع الحمل (تحتوي على ليفونورجيستريل و إيثينيل إيستراديول)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم دواء (مثل فينبروكومون/وارفارين) يؤثر على تجلط الدم، ينصح بمراقبة قيم تجلط الدم لديك بعد بدء العلاج باستخدام بانتوبرازول و إنهائه و خلال الاستخدام غير المنتظم.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم يلاحظ أي تفاعل عند استخدامه مع مضادات الحموضة. مضادات الحموضة هي بالعادة أدوية تستخدم لتقليل الحمض المعدي مباشرة وهي على شكل أقراص مضغ أو شراب.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسيت (يستخدم لعلاج إلتهاب المفاصل الروماتزمي و الصدفية و السرطان) &ndash; إذا كنت تستخدم ميثوتريكسيت قد يقوم طبيبك بوقف علاجك ب بانتوكسيرول لأن بانتوبرازول قد يزيد من مستويات الميثوتريكسيت بالدم.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوفوكسامين (يستخدم لعلاج الإكتئاب و أمراض نفسية أخرى) &ndash; إذا كنت تتناول فلوفوكسامين قد يقوم طبيبك بخفض الجرعة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج الإصابة بالعدوى)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز (Hypericum perforatum) (تستخدم لعلاج الاكتئاب الخفيف)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>يرجى اعلام طبيبك أو الصيدلي في حال كنت تأخذ أو أخذت مؤخرا أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>د. استخدام </strong><strong>بانتوكسيرول</strong><strong> مع الطعام أو الشراب</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا يوجد تفاعل مع الطعام أو الشراب بسبب طريقة الاستخدام.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>ه. الحمل و الرضاعة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">استشر طبيبك أو الصيدلي قبل استخدام هذا الدواء.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>الحمل</u></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>استشر طبيبك أو الصيدلي قبل استخدام هذا الدواء.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يجب استخدام هذا الدواء في الحمل فقط عندما تكون فائدة الدواء للأم تفوق الخطر المحتمل على الطفل الغير مولود.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>خلال فترة العلاج، إذا علمت أنك حامل، استشيري طبيبك او الصيدلي فورا.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>الرضاعة</u></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>استشر طبيبك أو الصيدلي قبل استخدام هذا الدواء.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يجب استخدام هذا الدواء في الأمهات المرضعات فقط عندما تكون فائدة الدواء للأم تفوق الخطر المحتمل على الطفل الغير مولود.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>و. القيادة واستخدام الآلات</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا تقم بالقيادة أو تستخدم الآلات إذا واجهت آعراض جانبية كالدوار أو اضطراب الرؤية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>ز. معلومات مهمة بشأن بعض مكونات </strong><strong>بانتوكسيرول</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يحتوي هذا المنتج الطبي على أقل من 1 ملي مول صوديوم ( 23 ملغم) في كل قارورة. لا أعراض جانبية متوقعة لهذه الجرعة من الصوديوم.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>يجب استخدام </em><em>بانتوكسيرول</em> <em>دائما كما أخبرك طبيبك او الصيدلي تماماً. يجب مراجعة طبيبك أو الصيدلي إن كنت غير متأكد.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>تعليمات الاستخدام الصحيح والجرعة/تكرار الاستخدام:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>لعلاج القرحة في الجزء العلوي من الأمعاء (قرحة الاثنى عشر)، قرحة المعدة (قرحة معدية) و التهاب المريء مصحوبا بارتداد حمض المعدة و الألم (التهاب المريء الجزري و مرض جريان رجوعي معدي مريئي):</u></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قارورة يوميا ( 40 ملغم بانتوبرازول).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><u>لعلاج متلازمة زولنغر-إليسون و الحالات التي يتم فيها انتاج زائد للحمض في المعدة:</u></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">2 قارورة يوميا ( 80 ملغم بانتوبرازول).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سيقرر طبيبك الجرعة وفقا لكمية الحمض المعدي المنتجة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا تم وصف أكثر من 2 قارورة ( 80 ملغم) يوميا من قبل طبيبك، فيجب إعطاؤك الحقن على جرعتين متساويتين.</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قد يبدأ طبيبك العلاج بجرعة مؤقتة من أكثر من 4 قارورات ( 160 ملغم) في اليوم. إذا كان من الضروري السيطرة على مستوى الحمض المعدي لديك بسرعة فإن الجرعة الإبتدائية من 160 ملغم ( 4 قارورات) كافية لتخفيض كمية الحمض في المعدة بشكل كافي.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>طريق الاستخدام و طريقته</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ينصح بالاستخدام الوريدي إن كان الاستخدام عبر الفم غير ممكن.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سيقوم الطبيب أو الممرضة بإعطاء بانتوكسيرول ببطء في الوريد.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الفئات العمرية المختلفة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الاستخدام في الاطفال</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا ينصح باستخدام هذه الحقنة في المرضى دون 18 سنة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الاستخدام في كبار السن</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">من الممكن استخدام بانتوكسيرول في المرضى المسنين بدون تعديل الجرعة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>قصور الكبد/الكلى</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا حاجة لتعديل الجرعة لمرضى اعتلال وظيفة الكلى.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">في المرضى الذين يعانون من مشاكل شديدة في الكبد، لا يجب أن تتعدى الجرعة اليومية 20 ملغم (نصف القارورة).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>إذا كان عندك الانطباع أن </em><em>بانتوكسيرول</em> <em>قوي جداً أو ضعيف جدا،ً يرجى الاتصال بطبيبك او الصيدلي.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>أ. إذا أعطيت بانتوكسيرول أكثر من اللازم:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا يوجد أعراض معروفة للجرعة الزائدة. إذا تم اعطاؤك بانتوكسيرول أكثر من المفروض، تحدث مع طبيبك أو الصيدلي.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>ب. إذا نسيت أن تستخدم بانتوكسيرول</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا نسيت أن تستخدم دوائك فلا تأخذ جرعة مضاعفة لتعويض الجرعة التي نسيتها. استمر في علاجك وفقا لجدول الجرعات المحدد من قبل طبيبك من الجرعة التالية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>ج. اذا توقفت عن استخدام بانتوكسيرول</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سيخبرك طبيبك عن مدة العلاج باستخدام بانتوكسيرول. لا تقم بإيقاف العلاج مبكراً حيث قد تعود أعراض مرضك أو قد تتفاقم.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>إذا كان لديك أي أسئلة إضافية حول استخدام هذا المنتج، فاسأل طبيبك أو الصيدلي.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>أعراض جانبية خطيرة:</strong></p><p dir="RTL"><strong>إذا واجهتك أي من الأعراض التالية، توقف عن استخدام </strong><strong>بانتوكسيرول</strong><strong> واعلم طبيبك فورا أو اتصل بقسم الطوارئ لدى أقرب مستشفى:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ردود فعل تحسسية خطيرة (نادر التكرار:</strong> قد يؤثر على ما يصل الى 1 من 1000 شخص): تورم اللسان و/أو الحلق، صعوبة في البلع، شرى (طفح قراصي)، صعوبة في التنفس، تورم تحسسي في الوجه (وذم ة كوينكه،/وذم ة وعائية)، دوار شديد مع تسارع ضربات القلب و التعرق الغزير.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالات الجلد الخطيرة (غير معروف التكرار:</strong> لا يمكن تقدير تكرارها من البيانات المتوفرة): طفح مؤلم مع تقرحات سريعة الانتشار على الجلد و تدهور حالتك العامة، خدوش (يتضمن نزيف خفيف) في العينين أو الأنف أو الفم/الشفاه أو الأعضاء التناسلية<strong>(</strong> قد تكون هذه علامات لتفاعلات جلدية خطيرة مثل متلازمة ستيفينز-جونسون، متلازمة لايل، حمامى عديدة الأشكال) و الحساسية للضوء.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالات خطيرة أخرى (غير معروف التكرار:</strong> لا يمكن تقدير تكرارها من البيانات المتوفرة): اصفرار الجلد أو بياض العينين <strong>(</strong>ضرر شديد لخلايا الكبد، اليرقان) أو الحمى، طفح و تضخم في الكلى يصاحبه تبوّل مؤلم، و ألم في أسفل الظهر (التهاب خطير في الكلى) والتي من المحتمل أن تؤدي إلى فشل كلوي.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هذه أعراض جانبية خطيرة جداً.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا كان لديك أي من هذه الأعراض فذلك يعني أن لديك حساسية خطيرة تجاه بانتوكسيرول. قد تحتاج إلى عناية طبية طارئة أو الذهاب للمستشفى.</p><p dir="RTL"><strong>أعراض جانبية محتملة:</strong></p><p dir="RTL">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كجميع الادوية، قد يسبب هذا الدواء أعراض جانبية ولكن قد لا تحصل عند الجميع.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>إذا واجهتك أي من الأعراض التالية أدناه، قم باعلام طبيبك.</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>شائع (قد يؤثر على 1 إلى 10 في 100 مريض):</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التهاب في جدار الوريد و تخثر الدم (التهاب الوريد الخثاري) في مكان حقن الدواء؛ سلائل حميدة في المعدة.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>غير شائع (قد يؤثر على 1 إلى 10 في 1000 مريض):</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">صداع؛ دوار؛ إسهال؛ الشعور بالمرض؛ التقيؤ؛ الانتفاخ و تطبل البطن (الريح)؛ الإمساك؛ جفاف الفم؛ ألم في البطن و الانزعاج؛ ردات فعل تحسسية مثل الفورة، الحكة، طفح جلدي؛ الشعور بالضعف، اضطرابات النوم.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">استخدام مثبط مضخة البروتون كبانتوبرازول خاصة لفترة تزيد عن السنة الواحدة، فإنه يزيد بشكل بسيط احتمال العرضة لكسر في الورك، الرسغ و العمود الفقري, اعلم طبيبك إذا كان لديك هشاشة عظام أو إذا كنت تأخذ الكورتيكوستيرويدات و التي تزيد احتمال العرضة لهشاشة العظام.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نادر (قد يؤثر على 1 إلى 10 في 10000 مريض):</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">اختلال أو فقدان كامل لحاسة التذوق؛ اضطرابات في الرؤية مثل تغيم الرؤية؛ شرى؛ ألم في المفاصل؛ ألم في العضلات؛ تغيرات في الوزن؛ ارتفاع درجة حرارة الجسم؛ حمى مرتفعة؛ تورم أطراف الجسم (وذمة محيطية)؛ ردات فعل تحسسية؛ الاكتئاب؛ تضخم الثدي لدى الرجال (تثدي الرجال).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نادر جدا (قد يؤثر على أقل من 1 في 10000 مريض):</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التوهان.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>غير معروف (لا يمكن تقدير تكرارها من المعلومات المتوفرة)</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">رؤية أو سماع أشياء غير موجودة في الحقيقة (الهلوسة) خاصة لدى المرضى العرضة لذلك، فقدان الانسجام بين الوقت و المكان، حالة من الارتباك الذهني، انخفاض مستوى الصوديوم في الدم (نقص صوديوم الدم). إذا كنت تستخدم بانتوكسيرول لمدة تزيد عن 3 أشهر، فمن الممكن أن تهبط مستويات المغنيسيوم في دمك. من الممكن ملاحظة مستويات المغنيسيوم المنخفضة (نقص مغنيسيوم الدم) من التعب، انقباضات العضلات الغير إرادية، التوهان، تشنجات، دوار، ارتفاع معدل خفقان القلب. قد يؤدي انخفاض مستويات المغنيسيوم إلى انخفاض مستويات البوتاسيوم أو الكالسيوم في دمك. قد يقرر طبيبك إجراء فحوصات دم بشكل منتظم من أجل مراقبة مستويات المغنيسيوم لديك.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأعراض الجانبية المحددة عبر فحوصات الدم</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>غير شائع (قد يؤثر على 1 إلى 10 في 1000 مريض):</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">زيادة في إنزيمات الكبد.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نادر (قد يؤثر على 1 إلى 10 في 10000 مريض):</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">زيادة مستوى بيليروبن في الدم؛ زيادة مستويات الدهون (ثلاثي الغليسيريد) في الدم؛ انخفاض حاد في كريات الدم البيضاء الحبيبية الدوّارة (الكرية البيضاء)، (مرتبطة بحمى مرتفعة).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نادر جدا (قد يؤثر على أقل من 1 في 10000 شخص):</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض في عدد كريات الدم المسؤولة عن تجلط الدم (صفيحات الدم)، (قد تؤدي هذه الحالة لأن تنزف بشكل أكثر من الطبيعي)؛ انخفاض في عدد كريات الدم البيضاء (الكرية البيضاء)، (هذه الحالة قد تؤدي إلى تكرر أعلى للالتهابات)؛ انخفاض غير طبيعي مشترك لكريات الدم الحمراء و كريات الدم البيضاء بالإضافة الى صفيحات الدم المسؤولة عن تجلط الدم.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>إذا أصبحت إحدى الأعراض الجانبية خطيرة، أو إذا لاحظت أي أعراض جانبية غير مذكورة في النشرة، يرجى اعلام طبيبك، مقدم الرعاية الصحية أو الصيدلي.</em></p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يحفظ بعيدا عن متناول و مرأى الأطفال.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ الانتهاء المذكور على الكرتونة أو القارورة. تاريخ الانتهاء يشير إلى آخر يوم لذلك الشهر.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يحفظ عند درجة حرارة الغرفة دون 30 &deg;م. يحفظ في علبته الأصلية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بعد إعادة التركيب أو إعادة التركيب و التخفيف، تم إظهار ثبات الاستخدام الكيميائي و الفيزيائي لمدة 12 ساعة على 30 &deg;م. يجب استخدام المنتج مباشرة من الناحية الميكروبيولوجية.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إذا لاحظت أي عيب في المنتج و/أو علبته، فلا تستخدم بانتوكسيرول.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يجب عدم التخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن طريقة التخلص من الأدوية الغير مطلوبة<em>.</em> هذه الإجراءات ستساعد على حماية البيئة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong><em>المادة الفعالة:</em></strong> كل قارورة تحتوي على 42.3 ملغم بانتوبرازول صوديوم ما يعادل 40 ملغم بانتوبرازول.</p><p><strong><em>المسوغ(ات):</em></strong> غير مطبق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong><em>ب. كيف يبدو </em><em>بانتوكسيرول و ما هي محتويات العلبة:</em></strong></p><p>بانتوكسيرول هو مسحوق للحقن أبيض. يقدم في قارورة زجاجية غير ملونة تحتوي على 40 ملغم مسحوق مختوم بسدادة مطاطية و مغلق بغطاء ألمنيوم بفتح علوي. يتم وضع قارورة واحدة في كرتونة مطبوعة معا مع النشرة الخاصة بها.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>حامل</strong><strong> </strong><strong>ترخيص</strong><strong> </strong><strong>التسويق</strong><strong>:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إم إن للمستحضرات الصيدلانية</p></td></tr><tr><td style="vertical-align:top"><p>Prof. Dr. B&uuml;lent Tarcan Sok., Pak İş Merkezi No: 5/1</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">34349 Gayrettepe - اسطنبول/تركيا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هاتف: +90 212 337 38 00</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فاكس: +90 212 337 38 01</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بريد إلكتروني: info@mn.com.tr</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>المصنعّ:</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">إم إن للمستحضرات الصيدلانية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">سانايي شارع رقم: 13</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ينيبوسنا، باهسيليفلر &ndash; اسطنبول/تركيا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هاتف: +90 212 454 76 00</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فاكس: +90 212 454 76 96</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بريد إلكتروني: info@mn.com.tr</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><em>لأي معلومات عن هذا المنتج الطبي، يرجى التواصل مع الوكيل المحلي لحامل ترخيص التسويق:</em></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">المملكة العربية السعودية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">مؤسسة الصالحية التجارية</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ص.ب. 991 الرياض 11421</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">هاتف: +966 11 464 6955</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">فاكس: +966 11 463 4362</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">موقع الكتروني: www.salehiya.com</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر تاريخ لاعتماد هذه النشرة هو 06/2018؛ رقم الاصدار: 03
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PANTOXEROL 40 mg Powder for Solution for Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:
Active Substance: Pantoprazole 40.0 mg (as sodium sesquihydrate).

Excipients: Not applicable.
For full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection.
White colored lyophilized powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Indicated in gastroesophageal reflux disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Gastric and duodenal ulcer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Zollinger-Ellison Syndrome and to be used in other pathological hypersecretory conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology/duration and frequency of administration</strong></p><p>This medicine should be administered by a healthcare professional and under appropriate medical supervision.</p><p>&nbsp;</p><p>Intravenous administration is recommended only if oral administration is not appropriate. Data are available on intravenous use for up to 7 days. Therefore, as soon as oral therapy is possible, treatment with PANTOXEROL IV injection should be discontinued and oral 40 mg pantoprazole should be administered instead.</p><p>&nbsp;</p><p><em><u>Gastric and duodenal ulcer, moderate and severe </u></em><em><u>gastroesophageal reflux</u></em><u> </u><em><u>treatment:</u></em></p><p>The recommended intravenous dose is one vial (40 mg pantoprazole) per day.</p><p><u>&nbsp;</u></p><p><em><u>Zollinger-Ellison-Syndrome and long-term treatment of other pathological hypersecretory conditions:</u></em></p><p>Treatment should be initiated with 80 mg daily dose. Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control.</p><p>&nbsp;</p><p>In case a rapid acid control is required, a starting 2&times;80 mg IV dose is sufficient to manage a decrease of acid output into the target range (&lt;10 mEq/h) within one hour in the majority of patients.</p><p>&nbsp;</p><p>When verified clinically it should be switched to oral treatment.</p><p><strong><em>&nbsp;</em></strong></p><p><strong>Method of administration:</strong></p><p>PANTOXEROL is administrated by intravenous injection.</p><p>&nbsp;</p><p>The solution is prepared by adding 10 ml sodium chloride 9 mg/ml (0.9%) solution for injection to the vial containing powder for injection. The prepared solution may be administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or 5% (55 mg/ml) or 10% (110 mg/ml) glucose solution.</p><p>&nbsp;</p><p>PANTOXEROL should not be mixed with other agents except the specified solvents.</p><p>&nbsp;</p><p>Intravenous injection should be administered over 2-15 minutes.</p><p>&nbsp;</p><p>After preparation the solution must be used within 12 hours.</p><p><strong>&nbsp;</strong></p><p><strong>Additional information regarding special populations:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Renal impairment</strong></p><p>No dose adjustment is necessary in patients with impaired renal function.</p><p><strong>&nbsp;</strong></p><p><strong>Hepatic impairment</strong></p><p>A daily dose of 20 mg pantoprazole (half a vial of 40 mg pantoprazole) should not be exceeded in patients with severe liver impairment. In addition, liver enzymes should be monitored during PANTOXEROL treatment. When elevation of liver enzymes was observed PANTOXEROL therapy should be discontinued.</p><p><strong>&nbsp;</strong></p><p><strong>Pediatric population</strong></p><p>Adequate clinical experience with treatment in children is not available. Therefore, PANTOXEROL Powder for solution for Injection should not be used for children below 18 years of age until further data become available.</p><p><strong>&nbsp;</strong></p><p><strong>Geriatric population</strong></p><p>No dose adjustment is necessary in elderly patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PANTOXEROL should not be used in patients with hypersensitivity to the active substance substituted benzimidazoles, or to any of the excipients in the composition.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hepatic Impairment:</u></p><p>In patients with severe liver impairment, the liver enzymes should be monitored regularly during therapy especially in long-term use. In the case of a rise of the liver enzymes, PANTOXEROL treatment should be discontinued.</p><p>&nbsp;</p><p><u>In presence of alarm symptoms:</u></p><p>In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, hematemesis, anemia or melena) and when gastric ulcer is suspected or present, malignancy should be excluded. As treatment with pantoprazole may alleviate symptoms and delay diagnosis.</p><p>&nbsp;</p><p>Further investigation is to be considered if symptoms persist despite adequate treatment.</p><p>&nbsp;</p><p><u>Sodium:</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per vial, i.e. is essentially &#39;sodium free&#39;. At this dose, it is not expected to cause any side effects related to sodium.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Co-administration with atazanavir:</u></p><p>Co-administration of atazanavir with proton pump inhibitors is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g. virus load) is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir. A pantoprazole dose of 20 mg per day should not be exceeded.</p><p>&nbsp;</p><p><u>Bone fractures:</u></p><p>Published several observational studies suggests that, proton pump inhibitors (PPI) may modestly increase fracture risk of hip, wrist or spine associated with osteoporosis. Fracture risk may increase in patients receiving high doses defined as multi daily doses and long-term PPI treatment (one year or more). Patients should use lowest dose and the shortest duration of PPI therapy appropriate to the condition being treated.</p><p>&nbsp;</p><p><u>Subacute cutaneous lupus erythematosus (SCLE):</u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the healthcare professional should consider stopping PANTOXEROL. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>&nbsp;</p><p><u>Hypomagnesemia:</u></p><p>Rarely symptomatic and asymptomatic hypomagnesemia has been reported in patients treated with PPIs for at least three months, and in most cases for a year. Serious adverse events include tetany, arrhythmia and seizure. In most affected patients, hypomagnesemia improved after magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>&nbsp;</p><p><u>The investigation in the interactions for neuroendocrine tumors:</u></p><p>Secondary to drug-induced reduction in gastric acid levels, serum chromogranin A (CgA) levels are increasing. Increased CgA level may lead to false-positive results in the diagnosis of neuroendocrine examination for tumors. Practitioners should give a temporarily pause to PPI therapy before evaluating CgA levels and if initial CgA levels are high, the test should be repeated. If a series of tests performed (i.e. for motorization), tests should be performed in the same laboratory due to reference ranges may vary between tests.</p><p>&nbsp;</p><p><u>Gastrointestinal infections caused by bacteria:</u></p><p>Pantoprazole, like all proton pump inhibitors, might be expected to increase the counts of bacteria normally present in the upper gastrointestinal tract. Treatment with PANTOXEROL may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as Salmonella, Campylobacter and Clostridium difficile (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of pantoprazole on the absorption of other medicinal products:</u></p><p>Because of profound and long lasting inhibition of gastric acid secretion, PANTOXEROL may reduce the absorption of drugs with a gastric pH dependent bioavailability, e.g some antifungals such as ketoconazole, itraconazole, posaconazole, and other medicine as erlotinib).</p><p>&nbsp;</p><p><u>HIV medications (atazanavir):</u></p><p>Co-administration of atazanavir and other HIV medications whose absorption is pH-dependent with proton-pump inhibitors might result in a substantial reduction in the bioavailability of these HIV medications and might impact the efficacy of these medicines. Therefore, the co-administration of proton pump inhibitors with atazanavir is not recommended (see section 4.4).</p><p><em>&nbsp;</em></p><p><u>Coumarin anticoagulants (phenprocoumon or warfarin):</u></p><p>Although no interaction during concomitant administration of phenprocoumon or warfarin has been observed in clinical pharmacokinetic studies, a few isolated cases of changes in International Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing period. Therefore, in patients treated with coumarin anticoagulants (e.g. phenprocoumon or warfarin), monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular use of pantoprazole.</p><p>&nbsp;</p><p><u>Methotrexate:</u></p><p>Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore in settings where high-dose methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered.</p><p><em>&nbsp;</em></p><p><u>Other interactions studies:</u></p><p>Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. The main metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include oxidation by CYP3A4. Interaction studies with drugs also metabolized with these pathways, like carbamazepine, diazepam, glibenclamide, nifedipine and an oral contraceptive containing levonorgestrel and ethinyl oestradiol did not reveal clinically significant interactions.</p><p>&nbsp;</p><p>Results from a range of interaction studies demonstrate that pantoprazole does not affect the metabolism of active substances metabolized by CYP1A2 (such as caffeine, theophylline), CYP2C9 (such as piroxicam, diclofenac, naproxen), CYP2D6 (such as metoprolol), CYP2E1 (such as ethanol) or does not interfere with p-glycoprotein related absorption of digoxin.</p><p>&nbsp;</p><p>There were no interactions with concomitantly administered antacids.</p><p>&nbsp;</p><p>Interaction studies have also been performed administering pantoprazole concomitantly with antibiotics such as clarithromycin, metronidazole, amoxicillin. No clinically relevant interactions were found.</p><p>&nbsp;</p><p><u>Medicinal products that inhibit or induce CYP2C19:</u></p><p>Inhibitors of CYP2C19 such as fluvoxamine could increase the systemic exposure of pantoprazole. A dose reduction may be considered for patients treated long-term with high doses of pantoprazole, or those with hepatic impairment.</p><p>Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John&acute;s wort (Hypericum perforatum) may reduce the plasma concentrations of PPIs that are metabolized through these enzyme systems.</p><p><strong>&nbsp;</strong></p><p><strong>Additional information regarding special populations:</strong></p><p>There is no interaction studies have been performed regarding special populations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General advice</strong></p><p>Pregnancy Category: B</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Women of childbearing potential/Birth control (Contraception)</strong></p><p>In specific tests with an oral contraceptive containing levonorgestrel and ethinyl oestradiol, no clinically relevant interactions were observed (see section 4.5).</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>There are limited data from the use of pantoprazole in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. PANTOXEROL should not be used during pregnancy unless clearly necessary.</p><p>In animal reproduction studies, mild fetotoxicity symptoms were observed at doses above 5 mg/kg. Caution must be exercised when used in pregnant women.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p>Animal studies have shown excretion of pantoprazole in breast milk. Excretion of pantoprazole in human milk has been reported. Therefore a decision on whether to continue/discontinue breast-feeding or to continue/discontinue PANTOXEROL therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of PANTOXEROL therapy for the women.</p><p>In nursing mothers pantoprazole should only be used if the benefit to mother outweighs the potential risk to the baby.</p><p><strong>&nbsp;</strong></p><p><strong>Fertility</strong></p><p>No evidence has been found for deterioration of fertility or teratogen effects in humans.</p><p>In animal reproduction studies there is no finding that is related to loss of fertility or teratogenicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). In case of occurrence of adverse events, patients should not drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of the safety profile</strong></p><p>Approximately 5% of patients can be expected to experience adverse drug reactions. The most commonly reported adverse reactions are diarrhea and headache, both occurring in approximately 1% of patients.</p><p>&nbsp;</p><p><strong>b. Tabulated summary of adverse reactions</strong></p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p>&nbsp;</p><p>The following adverse reactions were reported:</p><p>Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p><strong><u>&nbsp;</u></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p>Rare:</p></td><td><p>Agranulocytosis</p></td></tr><tr><td><p>Very rare:</p></td><td><p>Thrombocytopenia, leukopenia, pancytopenia</p></td></tr><tr><td colspan="2"><p><strong>Immune system disorders</strong></p></td></tr><tr><td><p>Rare:</p></td><td><p>Hypersensitivity (including anaphylactic reactions and anaphylactic shock)</p></td></tr><tr><td colspan="2"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td><p>Rare:</p></td><td><p>Hyperlipidemia and lipid increases (triglycerides, cholesterol), weight changes</p></td></tr><tr><td><p>Not known:</p></td><td><p>Hypernatremia, hypomagnesemia (see section 4.4), hypocalcaemia <sup>(1)</sup>, hypokalaemia</p></td></tr><tr><td colspan="2"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Sleep disorders</p></td></tr><tr><td><p>Rare:</p></td><td><p>Depression (and all aggravations)</p></td></tr><tr><td><p>Very rare:</p></td><td><p>Disorientation (and all aggravations)</p></td></tr><tr><td><p>Not known:</p></td><td><p>Hallucination; Confusion (especially in pre-disposed patients, as well as the aggravation of these symptoms in case of pre-existence)</p></td></tr><tr><td colspan="2"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Headache, dizziness</p></td></tr><tr><td><p>Rare:</p></td><td><p>Taste disorders</p></td></tr><tr><td><p>Not known:</p></td><td><p>Parasthesia</p></td></tr><tr><td colspan="2"><p><strong>Eye disorders</strong></p></td></tr><tr><td><p>Rare:</p></td><td><p>Disturbances in vision (blurred vision)</p></td></tr><tr><td colspan="2"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p>Common:</p></td><td><p>Fundic gland polyps (benign)</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Nausea/vomiting, abdominal distension and bloating, constipation, dry mouth, abdominal pain and discomfort, diarrhea</p></td></tr><tr><td colspan="2"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Liver enzymes increased (transaminases, &gamma;-GT)</p></td></tr><tr><td><p>Rare:</p></td><td><p>Bilirubin increased</p></td></tr><tr><td><p>Not known:</p></td><td><p>Hepatocellular injury, jaundice, hepatocellular failure</p></td></tr><tr><td colspan="2"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Itching, allergic reactions like rash/exanthema, eruption, pruritus</p></td></tr><tr><td><p>Rare:</p></td><td><p>Urticaria, angioedema</p></td></tr><tr><td><p>Not known:</p></td><td><p>Stevens-Johnson syndrome, Lyell syndrome, erythema multiforme, photosensitivity; Subacute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td colspan="2"><p><strong>Musculoskeletal and connective tissue</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Hip, wrist and spine fracture (see section 4.4.)</p></td></tr><tr><td><p>Rare:</p></td><td><p>Arthralgia, myalgia</p></td></tr><tr><td><p>Not known:</p></td><td><p>Muscle spasm<sup>(2)</sup></p></td></tr><tr><td colspan="2"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td><p>Not known:</p></td><td><p>Interstitial nephritis (with possible progression to renal failure)</p></td></tr><tr><td colspan="2"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td><p>Rare:</p></td><td><p>Gynaecomastia</p></td></tr><tr><td colspan="2"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td><p>Common:</p></td><td><p>Injection site thrombo-phlebitis</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Asthenia, fatigue and malaise</p></td></tr><tr><td><p>Rare:</p></td><td><p>Body temperature increased, edema peripheral</p></td></tr></tbody></table><p><sup>(1)</sup>Hypomagnesemia associated hypocalcemia</p><p><sup>(2)</sup>Muscle spasm due to electrolyte disturbance</p><p>&nbsp;</p><p><strong>c. Description of selected adverse reactions</strong></p><p><u>Gastroesophageal Reflux Disease ﴾GERD﴿</u></p><p>Safety in nine randomized comparative U.S. clinical trials in patients with GERD included 1,473 patients on oral pantoprazole ﴾20 mg or 40 mg﴿, 299 patients on an H<sub>2</sub>‐receptor antagonist, 46 patients on another proton pump inhibitor, and 82 patients on placebo. The most frequently occurring adverse reactions are listed in Table 1.</p><p>&nbsp;</p><p>The number of patients treated in comparative studies with I.V. pantoprazole is limited; however, the adverse reactions seen were similar to those seen in the oral studies. Thrombophlebitis was the only new adverse reaction identified with I.V. pantoprazole.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:652px"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 1: Adverse Reactions Reported in Clinical Trials of Adult Patients with GERD at a Frequency of &gt; 2%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pantoprazole Sodium</p><p>﴾n=1473﴿</p><p>%</p></td><td style="vertical-align:top"><p>Comparators</p><p>﴾n=345﴿</p><p>%</p></td><td style="vertical-align:top"><p>Placebo</p><p>﴾n=82﴿</p><p>%</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>12.2</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>8.5</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>8.8</p></td><td style="vertical-align:top"><p>9.6</p></td><td style="vertical-align:top"><p>4.9</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>9.8</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>6.2</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>6.1</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>2.4</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>3.7</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2.9</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>1.2</p></td></tr></tbody></table><p>&nbsp;</p><p>Additional adverse reactions that were reported for pantoprazole sodium in U.S. clinical trials with a frequency of &le; 2% are listed below by body system:</p><p><u>&nbsp;</u></p><p>Body as a Whole: allergic reaction, fever, photosensitivity reaction, facial edema, thrombophlebitis ﴾I.V. only﴿</p><p>Gastrointestinal: constipation, dry mouth, hepatitis</p><p>Hematologic: leukopenia ﴾reported in ex‐U.S. clinical trials only﴿, thrombocytopenia</p><p>Metabolic/Nutritional: elevated CPK ﴾creatine phosphokinase﴿, generalized edema, elevated triglycerides, liver function tests abnormal</p><p>Musculoskeletal: myalgia</p><p>Nervous: depression, vertigo</p><p>Skin and Appendages: urticaria, rash, pruritus</p><p>Special Senses: blurred vision</p><p>&nbsp;</p><p><strong>Zollinger</strong><strong>‐</strong><strong>Ellison Syndrome</strong></p><p>In clinical studies of Zollinger‐Ellison Syndrome, adverse reactions reported in 35 patients taking pantoprazole sodium 80 mg/day to 240 mg/day for up to 2 years were similar to those reported in adult patients with GERD.</p><p>&nbsp;</p><p><strong>d. Pediatric population</strong></p><p>Safety and effectiveness of pantoprazole sodium for injection in pediatric patients have not been established.</p><p><strong>&nbsp;</strong></p><p><strong>e. Other special populations</strong></p><p><em>&nbsp;</em></p><p><em>Geriatric Patients:</em></p><p>No age‐related differences in the safety profile of intravenous pantoprazole were seen in international trials involving 86 elderly ﴾&ge; 65 years old﴿ and 200 younger ﴾&lt; 65 years old﴿ patients with erosive esophagitis associated with GERD. Erosive esophagitis healing rates in the 107 elderly patients ﴾&ge; 65 years old﴿ treated with oral pantoprazole in U.S. clinical trials were similar to those found in patients under the age of 65. The incidence rates of adverse events and laboratory abnormalities in patients aged 65 years and older were similar to those associated with patients younger than 65 years of age.</p><p>&nbsp;</p><p><em>Gender:</em></p><p>No gender‐related differences in the safety profile of intravenous pantoprazole were seen in international trials involving 166 men and 120 women with erosive esophagitis associated with GERD. Erosive esophagitis healing rates in the 221 women treated with oral pantoprazole in U.S. clinical trials were similar to those found in men. The incidence rates of adverse reactions were also similar for men and women.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions:</u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&bull; Fax: +966-11-205-7662</p><p>&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&bull; Toll free phone: 8002490000</p><p>&bull; E-mail: npc.drug@sfda.gov.sa</p><p>&bull; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known symptoms of overdose in man.</p><p>It was administrated with up to 240 mg IV dose over 2 minutes and well tolerated.</p><p>As pantoprazole is extensively protein bound, it is not readily dialyzable. In the case of overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic Group: Proton pump inhibitors</p><p>ATC code: A02BC02</p><p>&nbsp;</p><p><u>Mechanism of action:</u></p><p>Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells.</p><p>Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H+, K+-ATPase enzyme. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and H<sub>2 </sub>receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the product is given orally or intravenously.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects:</u></p><p>The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long-term treatment (simple to adenomatoid hyperplasia). However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.</p><p>&nbsp;</p><p>Decreased gastric acid due to proton pump inhibitors or any other reason, leads to an increase in the counts of bacteria normally present in the gastrointestinal tract. Therapy with proton pump inhibitors may slightly increase gastrointestinal infection risk caused by <em>Salmonella</em> and <em>Camphylobacter </em>and <em>Clostridium difficile </em>possibly also in hospitalized patients.</p><p>&nbsp;</p><p>An influence of a long term treatment with pantoprazole exceeding one year cannot be completely ruled out on endocrine parameters of the thyroid according to results in animal studies.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety:</u></p><p><strong>Gastroesophageal Reflux Disease ﴾GERD﴿ Associated with a History of Erosive Esophagitis</strong></p><p>A multicenter, double‐blind, two‐period placebo‐controlled study was conducted to assess the ability of pantoprazole sodium for injection to maintain gastric acid suppression in patients switched from the oral dosage form of pantoprazole to the intravenous dosage form. Gastroesophageal reflux disease ﴾GERD﴿ patients ﴾n=65, 26 to 64 years; 35 female; 9 Black, 11 Hispanic, 44 White, 1 other﴿ with a history of erosive esophagitis were randomized to receive either 20 or 40 mg of oral pantoprazole once per day for 10 days ﴾period 1﴿, and then were switched in period 2 to either daily intravenous pantoprazole or placebo for 7 days, matching their respective dose level from period 1. Patients were administered all test medication with a light meal. Maximum acid output ﴾MAO﴿ and basal acid output ﴾BAO﴿ were determined 24 hours following the last day of oral medication ﴾day 10﴿, the first day ﴾day 1﴿ of intravenous administration and the last day of intravenous administration ﴾day 7﴿. MAO was estimated from a 1 hour continuous collection of gastric contents following subcutaneous injection of 6 mcg/kg of pentagastrin.</p><p>&nbsp;</p><p>This study demonstrated that, after 10 days of repeated oral administration followed by 7 days of intravenous administration, the oral and intravenous dosage forms of pantoprazole sodium 40 mg are similar in their ability to suppress MAO and BAO in patients with GERD and a history of erosive esophagitis ﴾see Table 2﴿. Also, patients on oral pantoprazole sodium who were switched to intravenous placebo experienced a significant increase in acid output within 48 hours of their last oral dose ﴾see Table 2﴿. However, at 48 hours after their last oral dose, patients treated with pantoprazole sodium for injection had a significantly lower mean basal acid output ﴾see Table 2﴿ than those treated with placebo.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 2: ANTISECRETORY EFFECTS (mEq/h) OF 40 mg PANTOPRAZOLE SODIUM for INJECTION AND 40 mg ORAL PANTOPRAZOLE SODIUM IN GERD PATIENTS WITH A HISTORY OF EROSIVE ESOPHAGITIS</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>* p&lt;0.0001 Significantly different from pantoprazole sodium for injection.</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Pantoprazole Sodium Delayed</strong><strong>‐</strong><strong>Release</strong></p><p><strong>Tablets</strong></p></td><td style="vertical-align:top"><p><strong>Pantoprazole Sodium for Injection</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>I.V.</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>DAY 10</strong></p></td><td style="vertical-align:top"><p><strong>DAY 7</strong></p></td><td style="vertical-align:top"><p><strong>DAY 7</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mean maximum acid</p><p>output</p></td><td style="vertical-align:top"><p>6.49</p><p>n=30</p></td><td style="vertical-align:top"><p>6.62</p><p>n=23</p></td><td style="vertical-align:top"><p>29.19*</p><p>n=7</p></td></tr><tr><td style="vertical-align:top"><p>Mean basal acid output</p></td><td style="vertical-align:top"><p>0.8</p><p>n=30</p></td><td style="vertical-align:top"><p>0.53</p><p>n=23</p></td><td style="vertical-align:top"><p>4.14*</p><p>n=7</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>To evaluate the effectiveness of pantoprazole sodium for injection as an initial treatment to suppress gastric acid secretion, two studies were conducted.</p><p>&nbsp;</p><p>Study 1 was a multicenter, double‐blind, placebo‐controlled, study of the pharmacodynamic effects of pantoprazole sodium for injection and oral pantoprazole sodium. Patients with GERD and a history of erosive esophagitis ﴾n=78, 20 to 67 years; 39 females; 7 Black, 19 Hispanic, 52 White﴿ were randomized to receive either 40 mg intravenous pantoprazole, 40 mg oral pantoprazole, or placebo once daily for 7 days. Following an overnight fast, test medication was administered and patients were given a light meal within 15 minutes. MAO and BAO were determined 24 hours following the last day of study medication. MAO was estimated from a 1 hour continuous collection of gastric contents following subcutaneous injection of 6 mcg/kg of pentagastrin to stimulate acid secretion. This study demonstrated that, after treatment for 7 days, patients treated with pantoprazole sodium for injection had a significantly lower MAO and BAO than those treated with placebo ﴾p&lt;0.001﴿, and results were comparable to those of patients treated with oral pantoprazole sodium ﴾see Table 3﴿.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Table 3: ANTISECRETORY EFFECTS (mEq/h) OF INITIAL TREATMENT WITH 40 mg PANTOPRAZOLE SODIUM for INJECTION AND 40 mg ORAL PANTOPRAZOLE SODIUM IN GERD PATIENTS WITH A HISTORY OF EROSIVE ESOPHAGITIS</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>* p&lt;0.0001 Significantly different from pantoprazole sodium for injection.</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Pantoprazole Sodium for Injection</strong></p><p><strong>DAY 7</strong></p></td><td style="vertical-align:top"><p><strong>Pantoprazole Sodium Delayed</strong><strong>‐</strong><strong>Release Tablets</strong></p><p><strong>DAY 7</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>DAY 7</strong></p></td></tr><tr><td style="vertical-align:top"><p>Maximum acid output ﴾mean &plusmn; SD﴿</p></td><td style="vertical-align:top"><p>8.4 &plusmn; 5.9</p><p>n=25</p></td><td style="vertical-align:top"><p>6.3 &plusmn; 6.6</p><p>n=22</p></td><td style="vertical-align:top"><p>20.9 &plusmn;</p><p>14.5*</p><p>n=24</p></td></tr><tr><td style="vertical-align:top"><p>Basal acid output ﴾mean &plusmn; SD﴿</p></td><td style="vertical-align:top"><p>0.4 &plusmn; 0.5</p><p>n=25</p></td><td style="vertical-align:top"><p>0.6 &plusmn; 0.8</p><p>n=22</p></td><td style="vertical-align:top"><p>2.8 &plusmn; 3*</p><p>n=23</p></td></tr></tbody></table><p>&nbsp;</p><p>Study 2 was a single‐center, double‐blind, parallel‐group study to compare the clinical effects of pantoprazole sodium for injection and oral pantoprazole sodium. Patients ﴾n=45, median age 56 years, 21 males and 24 females﴿ with acute endoscopically proven reflux esophagitis ﴾Savary/Miller Stage II or III﴿ with at least 1 of 3 symptoms typical for reflux esophagitis ﴾acid eructation, heartburn, or pain on swallowing﴿ were randomized to receive either 40 mg intravenous pantoprazole or 40 mg oral pantoprazole daily for 5 days. After the initial 5 days, all patients were treated with 40 mg oral pantoprazole daily to complete a total of 8 weeks of treatment. Symptom relief was assessed by calculating the daily mean of the sums of the average scores for these 3 symptoms and the daily mean of the average score for each of the symptoms separately. There was no significant difference in symptom relief between pantoprazole sodium for injection and oral pantoprazole sodium therapy within the first 5 days. A repeat endoscopy after 8 weeks of treatment revealed that 20 out of 23 ﴾87%﴿ of the pantoprazole sodium for injection plus oral pantoprazole sodium patients and 19 out of 22 ﴾86%﴿ of the oral pantoprazole sodium patients had endoscopically proven healing of their esophageal lesions.</p><p>&nbsp;</p><p>Data comparing pantoprazole sodium for injection to other proton pump inhibitors ﴾oral or I.V.﴿ or H<sub>2</sub>‐receptor antagonists ﴾oral or I.V.﴿ are limited, and therefore, are inadequate to support any conclusions regarding comparative efficacy.</p><p>&nbsp;</p><p><strong>Pathological Hypersecretion Associated with Zollinger</strong><strong>‐</strong><strong>Ellison Syndrome</strong></p><p><strong>&nbsp;</strong></p><p>Two studies measured the pharmacodynamic effects of 6 day treatment with pantoprazole sodium for injection in patients with Zollinger‐Ellison Syndrome ﴾with and without multiple endocrine neoplasia type I﴿. In one of these studies, an initial treatment with pantoprazole sodium for injection in 21 patients ﴾29 to 75 years; 8 female; 4 Black, 1 Hispanic, 16 White﴿ reduced acid output to the target level ﴾&le; 10 mEq/h﴿ and significantly reduced H<sup>+</sup> concentration and the volume of gastric secretions; target levels were achieved within 45 minutes of drug administration.</p><p>&nbsp;</p><p>In the other study of 14 patients ﴾38 to 67 years; 5 female; 2 Black, 12 White﴿ with Zollinger‐Ellison Syndrome, treatment was switched from an oral proton pump inhibitor to pantoprazole sodium for injection. Pantoprazole sodium for injection maintained or improved control of gastric acid secretion.</p><p>&nbsp;</p><p>In both studies, pantoprazole sodium for injection 160 or 240 mg per day in divided doses maintained basal acid secretion below target levels in all patients. Target levels were 10 mEq/h in patients without prior gastric surgery, and 5 mEq/h in all patients with prior gastric acid‐reducing surgery. Once gastric acid secretion was controlled, there was no evidence of tolerance during this 7 day study. Basal acid secretion was maintained below target levels for at least 24 hours in all patients and through the end of treatment in these studies ﴾3 to 7 days﴿ in all but 1 patient who required a dose adjustment guided by acid output measurements until acid control was achieved. In both studies, doses were adjusted to the individual patient need, but gastric acid secretion was controlled in greater than 80% of patients by a starting regimen of 80 mg q12h.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>General characteristics</p><p>Pharmacokinetics does not vary after single or repeated administration. Concomitant food intake does not affect AUC, maximum concentration or bioavailability.</p><p><strong>&nbsp;</strong></p><p><u>Absorption:</u></p><p>It is given directly into the bloodstream therefore absorption information not applicable.</p><p><strong>&nbsp;</strong></p><p><u>Distribution:</u></p><p>Volume of distribution is approximately 0.15 L/kg, distributing mainly in extracellular fluid. The serum protein binding is about 98%, primarily to albumin. Total serum clearance is about 0.1 L/hour/kg. Terminal half-life is approximately 1 hour.</p><p><strong>&nbsp;</strong></p><p><u>Biotransformation:</u></p><p>Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Pantoprazole metabolism is independent of the route of administration (intravenous or oral). The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulphate conjugation. Other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity.</p><p><strong>&nbsp;</strong></p><p><u>Elimination:</u></p><p>Renal elimination represents the major route of excretion (about 80%) for the metabolites of pantoprazole; the rest is excreted with the feces. The half-life of the main metabolite (about 1.5 hours) is not much longer than that of pantoprazole.</p><p>&nbsp;</p><p>After a single oral or intravenous dose of <sup>14</sup>C-labeled pantoprazole to healthy, normal metabolizer volunteers, approximately 71% of the dose was excreted in the urine, with 18% excreted in the feces through biliary excretion. There was no renal excretion of unchanged pantoprazole. Clearance is about 0.1 l/h/kg. There were a few cases of subjects with delayed elimination. Because of the specific binding of pantoprazole to the proton pumps of the parietal cell, the elimination half-life does not correlate with the much longer duration of action (inhibition of acid secretion).</p><p><strong>&nbsp;</strong></p><p><u>Linearity/non-linearity:</u></p><p>Pharmacokinetics of pantoprazole is linear in 10-80 mg dose range after both oral and intravenous administration.</p><p><em>&nbsp;</em></p><p><strong>a. Characteristics in patients:</strong></p><p>&nbsp;</p><p><u>Polymorphic metabolism:</u></p><p>Approximately 3% of the European population lack a functional CYP2C19 enzyme and are called poor metabolizers. In these individuals the metabolism of pantoprazole is probably mainly catalyzed by CYP3A4. After a single-dose administration of 40 mg pantoprazole, the mean area under the plasma concentration-time curve was approximately 6 times higher in poor metabolizers than in subjects having a functional CYP2C19 enzyme (extensive metabolizers). Mean peak plasma concentrations were increased by about 60%. These findings have no implications for the posology of pantoprazole.</p><p>&nbsp;</p><p><u>Renal Impairment:</u></p><p>No dose reduction is recommended in patients with impaired renal function (incl. dialysis patients). As with healthy subjects, pantoprazole&#39;s half-life is short. Only very small amounts of pantoprazole are dialyzed. Although the main metabolite has a moderately delayed half-life (2-3 h), excretion is still rapid and thus accumulation does not occur.</p><p>&nbsp;</p><p><u>Hepatic Impairment:</u></p><p>Although for patients with liver cirrhosis (classes A and B according to Child) the half-life values increased to between 7 and 9 h and the AUC values increased by a factor of 5-7, the maximum serum concentration only increased slightly by a factor of 1.5 compared with healthy subjects.</p><p>&nbsp;</p><p><u>Pediatric Population:</u></p><p>Following administration of single intravenous doses of 0.8 or 1.6 mg/kg pantoprazole to children aged 2-16 years there was no significant association between pantoprazole clearance and age or weight. AUC and volume of distribution were in accordance with data from adults.</p><p>&nbsp;</p><p><u>Older people:</u></p><p>A slight increase in AUC and Cmax in elderly volunteers compared with younger counterparts is also not clinically relevant.</p><p>&nbsp;</p><p>b. Pharmacokinetic/pharmacodynamic relationship:</p><p>Pantoprazole&rsquo;s favorable side effect profile and low incidence of drug-drug interactions make it ideal for using in all patient groups, including special populations.</p><p>&nbsp;</p><p>Several reports confirm that pantoprazole is a well-tolerated treatment even for long-term therapy with optimal tolerability. It is perfectly suited for use in patients taking concomitant therapies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard to humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.</p><p>&nbsp;</p><p>In the two-year carcinogenicity studies in rats neuroendocrine neoplasms were found. In addition, squamous cell papillomas were found in the fore stomach of rats. The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment. In the two-year rodent studies an increased number of liver tumors was observed in rats and in female mice and was interpreted as being due to pantoprazole&#39;s high metabolic rate in the liver.</p><p>&nbsp;</p><p>A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving the highest dose (200 mg/kg). The occurrence of these neoplasms is associated with the pantoprazole-induced changes in the breakdown of thyroxine in the rat liver. As the therapeutic dose in man is low, no harmful effects on the thyroid glands are expected.</p><p>&nbsp;</p><p>In animal reproduction studies, signs of slight fetotoxicity were observed at doses above 5 mg/kg.</p><p>&nbsp;</p><p>Investigations revealed no evidence of impaired fertility or teratogenic effects.</p><p>&nbsp;</p><p>Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentration of pantoprazole in the fetus is increased shortly before birth.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.&nbsp; &nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life is 24 months.

After reconstitution, or reconstitution and dilution, chemical and physical in use stability has been demonstrated for 12 hours at 30°C.

From a microbiological point of view, the product should be used immediately.

If not used immediately, in-use storage times and conditions are the responsibility of the user.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Stored at room temperature below 30&deg;C and in its package.</p><p>Keep container in the outer carton in order to protect from light.</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colorless type I glass vial, closed with gray bromobutyl rubber stopper and sealed by aluminum cap. Pack of 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused material should be disposed according to local disposal regulations.</p><p>&nbsp;</p><p>A ready-to-use solution is prepared by injecting 10 ml of sodium chloride 9 mg/ml (0.9%) solution for injection into the vial containing the powder. This solution may be administered directly or may be administered after mixing it with 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or glucose 55 mg/ml (5%) or 110 mg/ml (10%) solution for injection. Glass containers should be used for dilution.</p><p>&nbsp;</p><p>After reconstitution, or reconstitution and dilution, chemical and physical in use stability has been demonstrated for 12 hours at 30&deg;C.</p><p>&nbsp;</p><p>From a microbiological point of view, the product should be used immediately.</p><p>&nbsp;</p><p>PANTOXEROL should not be mixed with solvents other than those stated.</p><p>The medicinal product should be administered intravenously over 2-15 minutes.</p><p>&nbsp;</p><p>The contents of the vial are for single use only. Any product that has remained in the container or the visual appearance of which has changed (e.g. if cloudiness or precipitation is observed) should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MN Pharmaceuticals
Prof. Dr. Bülent Tarcan Sok. Pak Iş Merkezi No: 5/1
34349 Gayrettepe – Istanbul/TURKEY
Tel : +90.212.337 38 00
Fax : +90.212.337 38 01
e-mail : info@mn.com.tr


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>